Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2007

View Archived Issues

Esteve and AstraZeneca patents disclose therapeutic agents for metabolic disorders

Vertex updates recent developments, outlines 2007 goals

Ability of N-acetylcysteine to prevent acute renal failure in hypotensives unclear

Combined erythromycin/metoclopramide therapy shows promise in feed intolerance

Promising preclinical results for FK-734 in preventing transplant rejection

Inhibition of endocannabinoid degradation: a novel strategy for the treatment of Parkinson's disease

WHO awards prequalification status to Rotarix

Promising antitumor activity of combined therapy with docetaxel and the GHRH antagonist JMR-132

Viventia reviews late-stage antibody programs

Anavex Life Sciences reviews neurological pipeline

Lipomics to support Isis on metabolic drug testing

Promising results for Hylenex in INFUSE-Morphine study

MultiCell Technologies advances MCT-475 to preclinical development

Hemispherx updates avian flu program status

Kamada submits plans for phase II/III trial of aerosolized AAT

New phase IIb study evaluates NB-001 for herpes labialis

Rh-Apo2L begins phase II trials in China

Neocartilage begins clinical trial

Ariad advances phase III plans for AP-23573

Phase I results for SPI-1005 in noise-induced hearing loss reported at the ARO meeting

Ariad plans IND for AP-24534 for CML

Copernicus Therapeutics to receive further CFFT funding for CF gene therapy

Trend toward stabilization of CD4+ count in patients receiving Remune, IR-103

ELI-216 demonstrates euphoria blocking effect

Recent Gedeon Richter and Universitaet Wien patents disclose novel analgesic agents

Conditional approval for Prezista in E.U.

Priority review for ambrisentan NDA

Novel antiinfective agents disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.